Another Major Drug Approval for Regeneron

Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
More News
I am sharing some exciting and significant leadership transition news with you today. John Ravitz, the organization’s distinguished Executive Vice President and Chief Operating Officer, will retire effective December 31, 2026, after fifteen years of dedicated service to the Westchester business community. Noam Bramson, the former Mayor of New Rochelle, has been named Executive Vice […]
MorDance has been awarded a $2 million Capital Projects Fund grant from the New York State Council on the Arts (NYSCA) to support the development of the MorDance Performing Arts Center in Dobbs Ferry, marking a major milestone in the organization’s continued growth and commitment to arts education, performance, and community engagement throughout Westchester County. […]
A historic Yonkers property that housed a string of popular restaurants over the years has been given a new life as a self-storage facility, the latest development by Hampshire Management Company, which owns and operates a commercial real estate portfolio across the tri-state area. This is the company’s first self-storage project. CubeSmart Self-Storage will serve […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.